Online inquiry

IVTScrip™ mRNA-Anti-B7, BMS-224818(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4381MR)

This product GTTS-WQ4381MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD80&CD86 gene. The antibody can be applied in Kidney transplant rejection research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_005191.4; NM_001206924.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 941; 942
UniProt ID A0N0P2; P42081
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-B7, BMS-224818(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ4381MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8303MR IVTScrip™ mRNA-Anti-GLP1R, HM-12525A(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA HM-12525A
GTTS-WQ10341MR IVTScrip™ mRNA-Anti-IL17A&TNFSF13B, LY 3090106(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA LY 3090106
GTTS-WQ12631MR IVTScrip™ mRNA-Anti-ERBB2, OMNITARG™(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA OMNITARG™
GTTS-WQ15473MR IVTScrip™ mRNA-Anti-MAPT, UCB-0107(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA UCB-0107
GTTS-WQ5483MR IVTScrip™ mRNA-Anti-IL6, CDP 6038(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CDP 6038
GTTS-WQ2407MR IVTScrip™ mRNA-Anti-CD3E&EPCAM, AMG 110(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AMG 110
GTTS-WQ5694MR IVTScrip™ mRNA-Anti-GPNMB, CDX-011 (DOX)(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CDX-011 (DOX)
GTTS-WQ6672MR IVTScrip™ mRNA-Anti-MUC16, DMUC5754A(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA DMUC5754A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW